Hi R***k,
Great question,here’s a bit more color on our three-gate process, decision ownership, and model refresh cadence:
1. Gate 1: Initial Scoping
• Criteria: Alignment with N***h’s oncology/rare-disease focus, minimal data quality thresholds, acceptable IP freedom-to-operate, and a back-of-envelope commercial opportunity above our internal hurdle rate.
• Owners: BD Manager (you) plus Market Intelligence Analyst run the initial screen; VP of BD & Strategic Partnerships signs off to move into deep diligence.
2. Gate 2: Deep Dive
• Criteria: R&D data (preclinical, CMC, safety) meets go-forward thresholds, a refined market size and competitive map, and an NPV above our risk-adjusted internal rate. We also evaluate reimbursement and regulatory pathways.
• Owners: Cross-functional gate committee (R&D Head, Commercial Lead, Finance Director, and Licensing Manager) provides unanimous or majority approval.
3. Gate 3: Final Investment Recommendation
• Criteria: Confirmatory R&D readouts, final commercial model with validated pricing scenarios, negotiated term sheet alignment, and an ROI that satisfies executive targets.
• Owners: Executive Steering Committee (SVP BD, CFO, CMO) gives the final “go.”
Model Refresh Cadence
, We keep our Excel-based commercial model live: major updates at the close of each gate, monthly during the deep-dive phase, and ad-hoc whenever critical R&D milestones drop (e.g., tox data or regulatory feedback). Status changes and assumptions live in our shared Teams folder, ensuring everyone works off the latest version.
Look forward to walking through examples and your own experiences on Tuesday at 10:00 AM CST. Let me know if there’s anything else you’d like ahead of our call!
Best,
J***e
HR Recruiter, StrategyBrain